Company intelligence / Profile preview

KaloBios Pharmaceuticals

South San Francisco, California, United Statessec.gov ↗

Ownership: Private
Employees: ~17
Development stage: Phase 1

Overview

KaloBios was a struggling biotech company that faced multiple clinical trial failures. Their drug lenzilumab (KB003) was being developed for CMML after failing in asthma trials. The company filed for Chapter 11 bankruptcy in December 2015 and later emerged from bankruptcy protection.

Therapeutic areas: OncologyPulmonologyRare DiseasesInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

4 assets

KB-001

3 more assets in the full pipeline.

Request access →

Partnerships

NovartisSanofi Pasteur

Beyond the preview

Go deeper on KaloBios Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KaloBios Pharmaceuticals.

Explore the full profile